TransMedics Group Inc. (TMDX)
Live Earnings: Will TransMedics (TMDX) Rally After Earnings?
TransMedics Group reports its Q2 earnings after the bell. Wall Street current expectations stand at: Revenue: $147.74 million Adjusted EPS: $.43 We'll be updating this live blog with updates during the trading day and then once earnings hit the newswires will post a flurry of news and analysis.
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
Beyond analysts' top-and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Why TransMedics Remains A Buy Into 2026
TransMedics beat Q1 2025 estimates and raised full-year guidance, showing strong revenue and earnings growth. The company holds a unique market position with the only FDA-approved system for heart, lung, and liver transport. Profitability and margins are improving, though free cash flow, dilution, and a limited TAM remain concerns.
TransMedics: Q2 Analyst Estimates Will Fall Short
TransMedics has rebounded from a sharp sell-off by consistently beating guidance and demonstrating strong execution, restoring investor confidence. I anticipate Q2 2025 will deliver another earnings beat, with flight activity data suggesting sales could surpass analyst estimates. The company is showing clear operating leverage, manageable debt, and is building a vertically integrated logistics network in a niche market.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy
TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logistics costs, TMDX's execution, clinical edge, and management's ambitious growth targets support long-term market dominance. Valuation remains compelling: strong EPS growth and frequent estimate beats can sustain premium multiples as it scales.
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
TransMedics Group, Inc. (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
TransMedics: Extremely Undervalued And Extremely Innovative
TransMedics delivered a stellar Q1, beating revenue and EPS estimates, and raised FY25 guidance, showcasing robust growth and execution. I see significant upside from expanding organ utilization, especially with the upcoming kidney market and international opportunities, which meaningfully increase TAM. Despite risks like share dilution, logistics complexity, and regulatory hurdles, TMDX's moat and growth trajectory remain compelling.
Earnings Estimates Moving Higher for TransMedics (TMDX): Time to Buy?
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes TransMedics (TMDX) a New Buy Stock
TransMedics (TMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.
